Not applicableEnded earlyNCT01688011What this trial is testingConnect® Myeloid Disease RegistryWho this might be right forPrimary MyelofibrosisMyelodysplastic SyndromesLeukemia, Myeloid, Acute Celgene 2,013
Early research (Phase 1)Ended earlyNCT04637009What this trial is testingTAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsWho this might be right forAcute Myeloid LeukemiaMyeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm Astex Pharmaceuticals, Inc. 20
Testing effectiveness (Phase 2)Ended earlyNCT02431260What this trial is testingAn Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesWho this might be right forSolid Tumors and Hematologic Malignancy Incyte Corporation 69
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06664970What this trial is testingStudy on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With SelinexorWho this might be right forMDS Peking Union Medical College Hospital 39
Not applicableLooking for participantsNCT07143669What this trial is testingScreening Study for KIT D816V Mutated Mast Cell Disease in Select PopulationsWho this might be right forClonal Mast Cell DiseaseKIT D816V MutationSuspected KITD816V Mutated Clonal Mast Cell Disease Blueprint Medicines Corporation 450
Testing effectiveness (Phase 2)Looking for participantsNCT06859424What this trial is testingA Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationWho this might be right forAML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)Acute Leukemia (Category)+8 more Center for International Blood and Marrow Transplant Research 358
Testing effectiveness (Phase 2)Looking for participantsNCT05732961What this trial is testingLuspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN NeoplasmsWho this might be right forMyelodysplastic SyndromesMyeloproliferative NeoplasmAnemia H. Lee Moffitt Cancer Center and Research Institute 70
Early research (Phase 1)Study completedNCT05665530What this trial is testingPRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesWho this might be right forAggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more Prelude Therapeutics 86
Early research (Phase 1)Ended earlyNCT05609942What this trial is testingStudy of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesWho this might be right forAdvanced Systemic Mastocytosis Blueprint Medicines Corporation 9
Testing effectiveness (Phase 2)Study completedNCT02084563What this trial is testingStudy of Molecular and Genetic Abnormalities in Patients With Myeloid NeoplasmsWho this might be right forAcute Myeloid LeukemiaMyeloproliferative NeoplasmsMyelodysplastic Syndromes+1 more Hospital Israelita Albert Einstein 455
Testing effectiveness (Phase 2)Looking for participantsNCT06892223What this trial is testingAnti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical TransplantationWho this might be right forAcute Myeloid LeukaemiaMDS (Myelodysplastic Syndrome)MPN (Myeloproliferative Neoplasms) Istituto Clinico Humanitas 42
Testing effectiveness (Phase 2)Ended earlyNCT02711137What this trial is testingOpen-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesWho this might be right forSolid Tumors Incyte Corporation 137
Early research (Phase 1)Study completedNCT04473911What this trial is testingHaplo Peripheral Blood Sct In GVHD PreventionWho this might be right forGVHDAMLALL+13 more Zachariah Michael DeFilipp 25
Testing effectiveness (Phase 2)Looking for participantsNCT04996875What this trial is testing(Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisWho this might be right forAdvanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more Cogent Biosciences, Inc. 140
Not applicableLooking for participantsNCT07362225What this trial is testingMPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)Who this might be right forPolycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)+52 more MPN Research Foundation 5,000
Early research (Phase 1)Looking for participantsNCT04771572What this trial is testingStudy of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.Who this might be right forNon Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more Newave Pharmaceutical Inc 100
Early research (Phase 1)Ended earlyNCT02663518What this trial is testingA Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsWho this might be right forHematologic MalignanciesSolid Tumor Pfizer 249
Early research (Phase 1)Study completedNCT02493530What this trial is testingTGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaWho this might be right forMyelofibrosisPolycythemia Vera Vanderbilt-Ingram Cancer Center 60
Not applicableNot Yet RecruitingNCT07108023What this trial is testingHematological Disorders in EHPVO PatientsWho this might be right forExtrahepatic Portal Vein Obstruction (EHPVO)ThrombophiliaMyeloproliferative Neoplasms (MPN)+5 more Rahab Nady 115
Early research (Phase 1)Ended earlyNCT01066468What this trial is testingGlivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.Who this might be right forChronic Myeloid Leukemia (CML)Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN) Novartis Pharmaceuticals 3